

PATENT ASSIGNMENT

Electronic Version v1.1
 Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
Novo Nordisk A/S	03/16/2009
RECEIVING PARTY DATA	
Name:	TransTech Pharma, Inc.
Street Address:	4170 Mendenhall Oaks Parkway
City:	High Point
State/Country:	NORTH CAROLINA
Postal Code:	27265
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	13472090
CORRESPONDENCE DATA	
Fax Number:	(336)841-7020
Phone:	(336) 841-0300
Email:	srollins@ttpharma.com
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent via US Mail.</i>	
Correspondent Name:	Samuel B. Rollins
Address Line 1:	Transtech Pharma, Inc.
Address Line 2:	4170 Mendenhall Oaks Parkway
Address Line 4:	High Point, NORTH CAROLINA 27265
ATTORNEY DOCKET NUMBER:	7213.214-US NN-TTP3-16-09
NAME OF SUBMITTER:	Samuel B. Rollins
Total Attachments: 3 source=4_7213-214-US_Assignment_NN_to_TTP#page1.tif source=4_7213-214-US_Assignment_NN_to_TTP#page2.tif source=4_7213-214-US_Assignment_NN_to_TTP#page3.tif	

CH \$40.00 13472090

PATENT

PATENT ASSIGNMENT

WHEREAS, NOVO NORDISK A/S (hereafter "Assignor"), a corporation organized under the laws of Denmark, having an address of Novo Alle, DK-2880 Bagsvaerd, Denmark, is the owner of the patent(s) and/or patent application(s) set forth on Exhibit A hereto and the inventions described and claimed therein (hereafter the "Patent Property"); and



WHEREAS, TRANSTECH PHARMA, INC. (hereafter "Assignee"), a Delaware Corporation, having an address of 4170 Mendenhall Oaks Parkway, High Point, North Carolina, 27265, desires to acquired all right, title and interest in and to the Patent Property.

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, Assignor does hereby sell, assign, transfer and set over to Assignee, all its right, title and interest in and to the Patent Property, as well as all priority applications, provisionals, continuations, divisions, continuations-in-part, of said Patent Property, and all reissues, reexaminations, and extensions thereof, the same to be held and enjoyed by Assignee for its own use and benefit, and for the use and benefit of its successors, assigns, or legal representatives, to the end of the term or terms for which such Patent Property may be granted or reissued, as fully and entirely as the same would have been held and enjoyed by Assignor if this assignment and sale had not been made.

Assignor also assigns to Assignee, all right, title and interest in and to the inventions disclosed in said Patent Property throughout the world, including the right to file applications and obtain patents, utility models, industrial models and designs for said Patent Property in its own name throughout the world, including all rights to publish cautionary notices reserving ownership of said inventions and all rights to register said Patent Property in appropriate registries.

IN WITNESS WHEREOF, the parties have caused this Patent Assignment to be executed on the date and in the capacity shown below.

NOVO NORDISK A/S

CBIS By:  LNO By: 

Name: **Kåre Schultz**
Chief Operating Officer
Title: Novo Nordisk A/S

Name: **Lise Kingo**
Executive vice president and chief of staffs
Title: Corporate Relations

Date: 16 March 2009

Date: 16 March 2009

Exhibit A

Schedule of Patents/Patent Applications

U.S. Application No.	U.S. Registration No.
09/548,081	6,908,926
10/735,963	
11/962,455	
09/810,237	6,437,147
10/201,865	6,756,384
09/810,311	6,610,721
10/185,861	7,208,497
11/334,207	7,294,626
11/115,564	7,186,721
10/453,106	6,906,060
10/242,968	6,673,829
10/383,310	
10/267,620	7,064,135
60/903,503	
11/917,823	
10/354,341	7,101,898
10/891,553	
11/784,967	
60/934,514	